Aims Percutaneous patent foramen ovale (PFO) closure for secondary stroke prevention is
discussed controversially. Long-term data comparing different closure devices are limited …

Objectives: The present study was conducted to determine the safety of the transcatheter
closure of a patent foramen ovale (PFO) in patients with cryptogenic cerebral ischemia and …

Introduction—Patent foramen ovale (PFO) has been identified as a source of paradoxical
embolism and cryptogenic stroke. Low recurrence rates of ischaemic stroke after …

Objectives: The aim of this study was to assess the mid-term safety and efficacy of
percutaneous patent foramen ovale (PFO) closure using a bioabsorbable device (BioSTAR …

Objectives: The purpose of this study was to evaluate the efficacy and safety of device
closure of patent foramen ovale (PFO) versus antiplatelet therapy in patients with …

Of cryptogenic stroke patients younger than 55 years of age, up to 61% have had a patent
foramen ovale (PFO). Observational studies have revealed reductions in recurrent …

Objectives: The purpose of this study was to compare the efficacy of medical treatment with
percutaneous closure of patent foramen ovale (PFO). Background: Patients with cryptogenic …

Objectives To describe medium‐to long‐term follow‐up of patients undergoing device
closure of patent foramen ovale (PFO) for stroke or transient ischemic attack (TIA) …

Objective: To compare the safety and efficacy of percutaneous closure of patent foramen
ovale (PFO) with the Amplatzer PFO occluder (Amplatzer) or the PFO STAR device (STAR) …

Objectives To examine long‐term clinical outcomes with transcatheter patent foramen ovale
(PFO) closure versus medical therapy alone in patients with cryptogenic stroke. Background …